2507125

Source:http://linkedlifedata.com/resource/pubmed/id/2507125

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019638, umls-concept:C0027651, umls-concept:C0087111, umls-concept:C0205390, umls-concept:C0206034, umls-concept:C0301630, umls-concept:C0302592, umls-concept:C0851346, umls-concept:C1280500
pubmed:issue	9
pubmed:dateCreated	1989-11-20
pubmed:abstractText	The clinical efficacy of LC9018, a biological response modifier prepared from heat-killed Lactobacillus casei YTT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or III. The combination therapy with LC9018 demonstrated a significant effect on tumor reduction, compared with radiation therapy alone, at the cumulative doses of 15-Gy and 30-Gy external irradiation (P less than 0.05). Histologic study confirmed that LC9018 also enhanced the therapeutic effect of the irradiation. Moreover, LC9018 seemed to be useful in protecting the patients from leukopenia during radiotherapy. This study suggests that LC9018, when used in combination with radiotherapy, will be an effective adjuvant immunotherapeutic agent. More studies in a large series of patients will, however, be needed to establish its long-term efficacy, safety, and effects on both prognosis and enhancing radiotherapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/LC 9018, http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Attenuated
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0008-543X
pubmed:author	pubmed-author:AraiTT, pubmed-author:DokiyaTT, pubmed-author:HashimotoSS, pubmed-author:HirokawaYY, pubmed-author:IidaKK, pubmed-author:KitaMM, pubmed-author:OkawaTT, pubmed-author:TakegawaYY, pubmed-author:YamazakiKK
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	64
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1769-76
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:2507125-Adjuvants, Immunologic, pubmed-meshheading:2507125-Aged, pubmed-meshheading:2507125-Antineoplastic Agents, pubmed-meshheading:2507125-Bacterial Vaccines, pubmed-meshheading:2507125-Combined Modality Therapy, pubmed-meshheading:2507125-Drug Evaluation, pubmed-meshheading:2507125-Female, pubmed-meshheading:2507125-Humans, pubmed-meshheading:2507125-Lactobacillus casei, pubmed-meshheading:2507125-Leukocyte Count, pubmed-meshheading:2507125-Leukopenia, pubmed-meshheading:2507125-Middle Aged, pubmed-meshheading:2507125-Neoplasm Staging, pubmed-meshheading:2507125-Prognosis, pubmed-meshheading:2507125-Radiotherapy Dosage, pubmed-meshheading:2507125-Statistics as Topic, pubmed-meshheading:2507125-Uterine Cervical Neoplasms, pubmed-meshheading:2507125-Vaccines, Attenuated
pubmed:year	1989
pubmed:articleTitle	Phase II randomized clinical trial of LC9018 concurrently used with radiation in the treatment of carcinoma of the uterine cervix. Its effect on tumor reduction and histology.
pubmed:affiliation	Department of Radiology, Tokyo Women's Medical College, Japan.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial